Dressler Emily V, Liu Meng, Garcia Catherine R, Dolecek Therese A, Pittman Thomas, Huang Bin, Villano John L
Department of Biostatistical Sciences, School of Medicine Wake Forest School of Medicine, Winston Salem, NC.
Division of Cancer Biostatistics, University of Kentucky, Lexington, Kentucky.
Neurooncol Pract. 2019 Jan;6(1):37-46. doi: 10.1093/nop/npy014. Epub 2018 May 22.
Glioblastoma is an aggressive disease with a defined standard of care offering crucial survival benefits. Disparities in care may influence treatment decisions. This study seeks to evaluate potential patterns in care delivery using the National Cancer Database (NCDB).
We evaluated the NCDB from 1998 to 2011 for patients diagnosed with glioblastoma older than 20 years of age in order to describe current hospital-based demographics, rates of treatment modality by age, race, gender, likelihood of receiving treatment, and survival probabilities.
From 1998 to 2011, 100672 patients were diagnosed with glioblastoma in the United States. Of these, 54% were younger than 65 years of age, while 20% were 75 years of age or older. The most common type of treatment was surgery (73%), followed by radiation (69%) and chemotherapy (50%). Eleven percent of patients did not receive any form of therapy. Patients receiving no form of treatment were more likely to be older, female, black, or Hispanic. Tumors that did not involve brainstem, ventricles, or the cerebellum were associated with more aggressive treatment and better overall survival. The median survival was 7.5 months. The use of concomitant surgical resection, chemotherapy, and radiation demonstrated greater survival benefit.
Median survival for glioblastoma is significantly less than reported in clinical trials. Sociodemographic factors such as age, gender, race, and socioeconomic status affect treatment decisions for glioblastoma. The elderly are greatly undertreated, as many elderly patients receive no treatment or significantly less than standard of care.
胶质母细胞瘤是一种侵袭性疾病,有明确的标准治疗方案,能带来关键的生存益处。治疗差异可能会影响治疗决策。本研究旨在利用国家癌症数据库(NCDB)评估护理提供的潜在模式。
我们评估了1998年至2011年NCDB中年龄超过20岁的胶质母细胞瘤患者,以描述当前基于医院的人口统计学特征、按年龄、种族、性别划分的治疗方式发生率、接受治疗的可能性以及生存概率。
1998年至2011年,美国有100672例患者被诊断为胶质母细胞瘤。其中,54%年龄小于65岁,而20%年龄在75岁及以上。最常见的治疗方式是手术(73%),其次是放疗(69%)和化疗(50%)。11%的患者未接受任何形式的治疗。未接受任何形式治疗的患者更可能是老年人、女性、黑人或西班牙裔。不累及脑干、脑室或小脑的肿瘤与更积极的治疗和更好的总体生存相关。中位生存期为7.5个月。同时进行手术切除、化疗和放疗显示出更大的生存益处。
胶质母细胞瘤的中位生存期明显低于临床试验报告的结果。年龄、性别、种族和社会经济地位等社会人口学因素会影响胶质母细胞瘤的治疗决策。老年人治疗严重不足,因为许多老年患者未接受治疗或接受治疗明显少于标准治疗。